From centrocytic to mantle cell lymphoma: A clinicopathologic and molecular review of 3 decades

Human Pathology

Volumn 33, Issue 1, 2002, Pages 7-20

  Swerdlow, Steven H ^a   Williams, Michael E ^b  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF VIRGINIA   (United States)

Author keywords

Cyclin D1; Genotype; Mantle cell lymphoma; Non Hodgkin lymphoma; T(11; 14)

Indexed keywords

CD23 ANTIGEN; CD5 ANTIGEN; CELL PROTEIN; COMMON ACUTE LYMPHOBLASTIC LEUKEMIA ANTIGEN; CYCLIN D1; PROTEIN FMC7; PROTEIN P16; PROTEIN P53; UNCLASSIFIED DRUG;

B CELL LYMPHOMA; BLAST CELL; CELL CYCLE; CELL PROLIFERATION; CELL STRUCTURE; CYTOGENETICS; DISEASE SEVERITY; DNA MICROARRAY; GENE DELETION; GENE MUTATION; GENE OVEREXPRESSION; GENE TRANSLOCATION; GENOTYPE; HISTOPATHOLOGY; HUMAN; MANTLE CELL LYMPHOMA; PATHOGENESIS; REVIEW;

EID: 0036156695     PISSN: 00468177     EISSN: None     Source Type: Journal    
DOI: 10.1053/hupa.2002.30221     Document Type: Article

References (134)

1. Cytological and functional criteria for the classification of malignant lymphomata
2. Mantle-cell lymphoma
3. Centrocytic lymphoma: A distinct clinicopathologic, immunophenotypic, and genotypic entity
4. Histopathology of malignant lymphomas
5. Lymphocytic lymphoma of intermediate differentiation-mantle zone lymphoma: A distinct subtype of B-cell lymphoma
6. Lymphocytic lymphoma of intermediate differentiation. Morphologic and immunophenotypic spectrum and clinical correlations
7. Malignant lymphoma, intermediate lymphocytic type: A clinicopathologic study of 42 cases
8. Mantle-zone lymphoma: A follicular variant of intermediate lymphocytic lymphoma
9. Classification of non-Hodgkin's lymphomas
10. Morphological and immunological definition of a malignant lymphoma derived from germinal-centre cells with cleaved nuclei (centrocytes)
11. Centrocytic lymphoma: A distinct clinicopathologic and immunologic entity. A multiparameter study of 18 cases at diagnosis and relapse
12. Neoplastic and reactive follicles within B-cell malignant lymphomas. A morphological and immunological study of 30 cases
13. Infrequent normal B lymphocytes express features of B-chronic lymphocytic leukemia
14. Immunohistologic characterization of two malignant lymphomas of germinal center type (centroblastic/centrocytic and centrocytic) with monoclonal antibodies. Follicular and diffuse lymphomas of small-cleaved-cell type are related but distinct entities
15. Centrocytic lymphoma: A morphometric study with comparison to other small cleaved follicular center cell lymphomas and genotypic correlates
16. Mantle cell lymphoma. A proposal for unification of morphologic, immunologic, and molecular data
17. European Lymphoma Task Force (ELTF): Report of the workshop on Mantle Cell Lymphoma (MCL)
18. Mantle cell lymphoma: A clinicopathologic study of 80 cases
19. Mantle cell lymphoma: Natural history defined in a serially biopsied population over a 20-year period
20. A clinical analysis of two indolent lymphoma entities: Mantle cell lymphoma and marginal zone lymphoma (including the mucosa-associated lymphoid tissue and monocytoid B-cell subcategories): A Southwest Oncology Group study
21. Mantle cell lymphoma: Correlation of clinical outcome and biologic features with three histologic variants
22. Homing receptor alpha 4beta7 integrin expression predicts digestive tract involvement in mantle cell lymphoma
23. Evidence for need of upper and lower endoscopies with biopsy in staging of asymptomatic patients with aggressive mantle cell lymphoma (MCL)
24. The morphologic spectrum of non-Hodgkin's lymphomas with BCL1/cyclin D1 gene rearrangements
25. Classification of small B-cell lymphoid neoplasms using a paraffin section immunohistochemical panel
26. Molecular cloning of the chromosomal breakpoint of B-cell lymphomas and leukemias with the t(11;14) chromosome translocation
27. A novel cyclin encoded by a bell-linked candidate oncogene
28. Isolation of three novel human cyclins by rescue of G1 cyclin (Cln) function in yeast
29. Human D-type cyclin
30. Characterization of a candidate bcl- 1 gene
31. Identification and cloning of two overexpressed genes, U21BS1/PRAD1 and EMS1, within the amplified chromosome 11q13 region in human carcinomas
32. Break in the BCL1 locus is closely associated with intermediate lymphocytic lymphoma subtype
33. Genotypic characterization of centrocytic lymphoma: Frequent rearrangement of the chromosome 11 bcl-1 locus
34. Association of bcl-1 rearrangements with lymphocytic lymphoma of intermediate differentiation
35. Rearrangement of the chromosome 11 bcl-1 locus in centrocytic lymphoma: Analysis with multiple breakpoint probes
36. Centrocytic lymphoma: A B-cell non-Hodgkin's lymphoma characterized by chromosome 11 bcl-1 and PRAD 1 rearrangements
37. Characterization of chromosome 11 translocation breakpoints at the bcl-1 and PRAD1 loci in centrocytic lymphoma
38. Chromosome 11 translocation breakpoints at the PRAD1/cyclin D1 gene locus in centrocytic lymphoma
39. Chromosome t(11;14)(q13;q32) breakpoints in centrocytic lymphoma are highly localized at the bcl-1 major translocation cluster
40. Detection of bcl-1 gene rearrangement and B-cell clonality in mantle cell lymphoma using formalin-fixed, paraffin-embedded tissues
41. Polymerase chain reaction detection of the t(11;14) translocation involving the bcl-1 major translocation cluster in mantle cell lymphoma
42. Antigen expression and polymerase chain reaction amplification of mantle cell lymphomas
43. Quantitative real-time reverse transcription-PCR assay for cyclin D1 expression: Utility in the diagnosis of mantle cell lymphoma
44. Expression of cyclin D1 protein in centrocytic/mantle cell lymphomas with and without rearrangement of the BCL1/cyclin D1 gene
45. Cyclin D1 expression in non-Hodgkin's lymphomas. Detection by immunohistochemistry
46. In situ hybridization detection of cyclin D1 mRNA in centrocytic/mantle cell lymphoma
47. Mantle cell/centrocytic lymphoma: Molecular and phenotypic analysis including analysis of the bcl-1 major translocation cluster by PCR
48. Cyclin D1 overexpression in non-Hodgkin's lymphoma with chromosome 11 bcl-1 rearrangement
49. Multiparameter immunohistochemical analysis of the cell cycle proteins cyclin D1, Ki-67, p21WAF1, p27KIP1, and p53 in mantle cell lymphoma
50. Optimized cyclin D1 immunoperoxidase staining in mantle cell lymphoma
51. Significance of cyclin D1 overexpression for the diagnosis of mantle cell lymphoma: A clinico-pathologic comparison of cyclin D1-positive MCL and cyclin D1-negative MCL-like B-cell lymphoma
52. Direct visualization of dispersed 11q13 chromosomal translocations in mantle cell lymphoma by multicolor DNA fiber fluorescence in situ hybridization
53. Bcl-1/cyclin D1 in malignant lymphoma
54. Detection of 11q13 rearrangements in hematologic neoplasias by double-color fluorescence in situ hybridization
55. Detection of translocation t(11;14)(q13;q32) in mantle cell lymphoma by fluorescence in situ hybridization
56. Multiple myeloma and the translocation t(11;14)(q13;q32): A report on 13 cases
57. Cytogenetics in multiple myeloma: A multicenter study of 24 patients with t(11;14)(q13;q32) or its variant
58. Multicolor spectral karyotyping identifies new recurring breakpoints and translocations in multiple myeloma
59. Molecular analysis of bcl-1/IgH junctional sequences in mantle cell lymphoma: Potential mechanism of the t(11;14) chromosomal translocation
60. Cellular origin of human B-cell lymphomas
61. Dysregulation of cyclin D1 by translocation into an IgH gamma switch region in two multiple myeloma cell lines
62. Multiple myeloma: Increasing evidence for a multistep transformation process
63. Involvement of the CCND1 gene in hairy cell leukemia
64. Increased expression of the PRAD-1/CCND1 gene in hairy cell leukaemia
65. Blastic mantle cell leukemia: An unusual presentation of blastic mantle cell lymphoma
66. Absence of cyclin D1 protein expression in splenic marginal zone lymphoma
67. Differential expression of cyclin D1 in mantle cell lymphoma and other non-Hodgkin's lymphomas
68. Cancer cell cycles
69. Cyclins and cancer. II: Cyclin D and CDK inhibitors come of age
70. Role of the cyclin-dependent kinase inhibitors in the development of cancer
71. Growth suppression by p18, a p1INK4/MTS1- and p1INK4B/MTS2-related CDK6 inhibitor, correlates with wild-type pRb function
72. Novel INK4 proteins, p19 and p18, are specific inhibitors of the cyclin D-dependent kinases CDK4 and CDK6
73. Identification of human and mouse p19, a novel CDK4 and CDK6 inhibitor with homology to p16ink4
74. Cyclins D1 and D2 are differentially expressed in human B-lymphoid cell lines
75. Regulated genomic instability and neoplasia in the lymphoid lineage
76. Overexpression of cyclin D1 in rat fibroblasts causes abnormalities in growth control, cell cycle progression and gene expression
77. Cyclin D1 induction in breast cancer cells shortens G1 and is sufficient for cells arrested in G1 to complete the cell cycle
78. Overexpression of mouse D-type cyclins accelerates G1 phase in rodent fibroblasts
79. G1 phase progression: Cycling on cue
80. Oncogenic activity of cyclin D1 revealed through cooperation with Ha-ras: Link between cell cycle control and malignant transformation
81. Function of a human cyclin gene as an oncogene
82. Mammary hyperplasia and carcinoma in MMTV-cyclin D1 transgenic mice
83. Cyclin D1/bcl-1 cooperates with myc genes in the generation of B-cell lymphoma in transgenic mice
84. Cyclin D1 transgene impedes lymphocyte maturation and collaborates in lymphomagenesis with the myc gene
85. Molecular characterization of 11q deletions points to a pathogenic role of the ATM gene in mantle cell lymphoma
86. Somatic ATM mutations indicate a pathogenic role of ATM in B-cell chronic lymphocytic leukemia
87. Mantle cell lymphoma is characterized by inactivation of the ATM gene
88. p53 in hematologic malignancies
89. p53 mutation is associated with progression in follicular lymphomas
90. p53 mutations are associated with histologic transformation of follicular lymphoma
91. Absence of WAF1 mutations in a variety of human malignancies
92. Homozygous deletions of p16/MTS1 gene are frequent but mutations are infrequent in childhood T-cell acute lymphoblastic leukemia
93. p16INK4A and p15INK4B gene deletions in primary leukemias
94. Deletions and rearrangement of CDKN2 in lymphoid malignancy
95. Deletion of cyclin-dependent kinase 4 inhibitor genes P15 and P16 in non-Hodgkin's lymphoma
96. Deletions of the cyclin-dependent kinase inhibitor genes p16INK4A and p15INK4B in non-Hodgkin's lymphomas
97. Homologous MTS1 (p16INK4A) deletion in primary tumor cells of 163 leukemic patients
98. Mutational analysis of the CDKN2 (MTS1/p16ink4A) gene in primary B-cell lymphomas
99. Loss of the cyclin-dependent kinase 4-inhibitor (p16; MTS1) gene is frequent in and highly specific to lymphoid tumors in primary human hematopoietic malignancies
100. Hemizygous p16(INK4A) deletion in pediatric acute lymphoblastic leukemia predicts independent risk of relapse
101. A cell cycle regulator potentially involved in genesis of many tumor types
102. Refined mapping of genomic rearrangements involving the short arm of chromosome 9 in acute lymphoblastic leukemias and other hematologic malignancies
103. Overexpression of cyclin D1 in chronic B-cell malignancies with abnormality of chromosome 11q13
104. Mutational analysis of the p16 family cyclin-dependent kinase inhibitors p15INK4b and p18INK4c in tumor-derived cell lines and primary tumors
105. Non-Hodgkin's lymphomas with t(11;14)(q13;q32): A subset of mantle zone/intermediate lymphocytic lymphoma?
106. Frequent p53 gene involvement in splenic B-cell leukemia/lymphomas of possible marginal zone origin
107. p53 mutations in mantle cell lymphoma are associated with variant cytology and predict a poor prognosis
108. Deletions and loss of expression of p 16INK4a and p21Waf1 genes are associated with aggressive variants of mantle cell lymphomas
109. p53 gene mutations and protein overexpression are associated with aggressive variants of mantle cell lymphomas
110. p53 overexpression as a marker of poor prognosis in mantle cell lymphomas with t(11;14) (q13;q32)
111. Concurrent disruption of cell cycle associated genes in mantle cell lymphoma: A genotypic and phenotypic study of cyclin D1, p16, p 15, p53 and pRb
112. The cytomorphological spectrum of mantle cell lymphoma is reflected by distinct biological features
113. Increased proteasome degradation of cyclin-dependent kinase inhibitor p27 is associated with a decreased overall survival in mantle cell lymphoma
114. Mantle cell lymphomas lack expression of p27Kip1, a cyclin-dependent kinase inhibitor
115. MTS1/MTS2 (p15/p16) deletions and p53 mutations in mantle cell (centrocytic) lymphoma
116. p16(INK4a) gene inactivation by deletions, mutations, and hypermethylation is associated with transformed and aggressive variants of non-Hodgkin's lymphomas
117. Analysis of the cyclin-dependent kinase inhibitors p18 and p19 in mantle-cell lymphoma and chronic lymphocytic leukemia
118. Alterations of the cyclin D1/p16-pRB pathway in mantle cell lymphoma
119. The MDM2 oncogene overexpression in chronic lymphocytic leukemia and low-grade lymphoma of B-cell origin
120. Increased number of chromosomal imbalances and high-level DNA amplifications in mantle cell lymphoma are associated with blastoid variants
121. Gain of 3q and deletion of 11q22 are frequent aberrations in mantle cell lymphoma
122. Secondary chromosome changes in mantle cell lymphoma
123. Translocation (11;14) (q13;q32) and preferential involvement of chromosomes 1, 2, 9, 13, and 17 in mantle cell lymphoma
124. Genetics of small lymphocyte disorders
125. Acquired chromosome 11q deletion involving the ataxia teleangiectasia locus in B-cell non-Hodgkin's lymphoma: Correlation with clinicobiologic features
126. A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma
127. Mantle cell lymphoma
128. Hyper-CVAD and high-dose methotrexate/cytarabine followed by stem-cell transplantation: An active regimen for aggressive mantle-cell lymphoma
129. Allogeneic hematopoietic transplantation for mantle-cell lymphoma: Molecular remissions and evidence of graft-versus-malignancy
130. Rituxan/CHOP induction therapy in newly diagnosed patients with mantle cell lymphoma
131. Transplant-lite: Induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies
132. High-dose therapy with stem cell transplantation for mantle cell lymphoma: Results and prognostic factors, a single center experience
133. Phase I clinical and pharmacokinetic study of Bcl-2 antisense oligonucleotide therapy in patients with non-Hodgkin's lymphoma